MXCT - Gene editing stocks mixed despite world's first CRISPR drug approval
2023-11-16 15:54:01 ET
More on CRISPR Therapeutics
- CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval
- Risk And Reward: Evaluating Crispr's Exa-Cel For Sickle Cell
- Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy
- Biggest stock movers today: Alibaba, Walmart, Cisco Systems, Palo Alto Networks and more
- UK approves world-first sickle cell gene-editing therapy from Vertex-Crispr
For further details see:
Gene editing stocks mixed despite world’s first CRISPR drug approval